How a Biopharmaceutical Drug Development Company Established its Presence in a New Industry on Newswire's Media Advantage Plan CASE STUDY: Gb Sciences| A Case Study on Newswire's Media Advantage Plan Gb Sciences, Inc. (OTCQB: GBLX) is a plant-based research and biopharmaceutical drug development company creating patented, disease-targeted formulations of plant-inspired therapeutic mixtures for the prescription drug market through GbS Global Biopharma, its Canadian subsidiary. PhAROSTM, Gb Sciences' novel AI-accelerated drug discovery platform, has yielded five issued U.S. patents and three issued international patents, as well as another 59 U.S. and international patent-pending applications. In 2021, Gb Sciences began proof-of-concept studies with Michigan State University to support the u

Join for free to read